TP53 and myelodysplastic syndrome: Therefore, restricting eprenetapopt to patients with TP53-mutated MDS, while being an area of unmet therapeutics need, may be obscuring the therapeutic benefit that eprenetapopt could provide to a wider range of patients with MDS, especially MDS-RS.